In Shanghai, the first commercial implantation of NEO for restoring grip was performed. On July 13, doctors at Huashan Hospital implanted NEO in a patient who had been living with the consequences of a cervical spinal cord injury for ten years. During the operation, the system recorded stable signals from the brain's surface, and after the procedure, the patient's condition remained stable. Data on grip recovery, independence in daily life, and long-term safety for this patient have not been published yet. NEO is an implantable neurointerface that translates movement intention into a command for an external device. The NEO electrodes lie on the brain's hard shell, between the skull and brain tissue. The system recognizes the intention to clench a fist and sends a command to a pneumatic glove, which bends the fingers and helps hold an object. On March 13, the Chinese regulator registered NEO for restoring grip in adults with cervical spinal cord injuries. The registration allowed the sale and clinical use of the device. This operation became the first case where NEO was installed in a patient through a commercial route. According to SCMP, within four months after registration, the manufacturer started production, began working with hospitals, and selecting patients. The Shanghai supplementary medical insurance program Huahui Bao included implantation materials in its coverage: it reimburses 30% of eligible expenses, up to 150,000 yuan per year. The limit applies specifically to the materials, not the entire procedure.

🔗 Read original →

An implant in the sensory cortex has been restoring the sense of touch to people with spinal cord injuries for ten years. Five participants were implanted with microelectrode arrays - sets of thin electrodes - in the section of the sensory cortex associated with the hand. A study published on July 15 in Science Translational Medicine collected data over implantation periods of two to ten years: over 168 million electrical impulses and 27 cumulative years of device operation. To take a glass, a person must not only send a command to their hand to "squeeze fingers," but the brain must also constantly receive feedback from the hand: whether the fingers have touched a surface, how hard they are pressing, and whether the object is slipping. After a severe spinal cord injury, this feedback disappears. A person can control a robotic hand through a neurointerface and still not feel its contact with an object. Intracortical microstimulation delivers short electrical impulses directly to the sensory cortex - a section of the brain with a body map. Different points on this map are associated with different parts of the hand. When a microelectrode stimulates the corresponding point on the map, a person feels touch in the corresponding finger or palm. A sensor on a robotic hand can be connected to this electrode and convert contact with an object into artificial touch. Artificial touch has already been helpful in a task with a robotic hand. In a 2021 study, a participant with tetraplegia performed the task in an average of 20.9 seconds with only vision and in 10.2 seconds when artificial touch was added to vision. A neuroprosthesis for everyday use requires that the electrodes, brain tissue, and sensations remain functional for years. In a new study, the group of Charles Greenberg, Robert Gaunt, and Jennifer Collinger tracked this sensory channel for up to ten years. Each of the five participants was implanted with two electrode arrays in the sensory cortex. Over this time, the researchers delivered over 168 million impulses. They did not detect any serious complications associated with stimulation or signs that the impulses themselves were degrading the performance of the electrodes. The sensations continued to arise in the hand and remained localized. In one participant, after ten years, 60% of the electrodes were still working reliably; on average, across the group, 64% were working, with a spread of 13% between participants. A slowly increasing current was required for sensation: approximately 3.5 microamperes more per year. Rare sensations could briefly persist after the impulse was turned off, but did not require treatment. Two days ago, bioengineer Takeshi Kozaei called the preservation of living tissue around the electrode a condition for a neurointerface to last decades. In this study, part of the electrodes gradually lose sensitivity. A sensor on the hand must transmit a signal to the same point on the hand map in the cortex for years, and the system must maintain the sensation of contact while individual electrodes fail.

🔗 Read original →

Zoledronate has altered signs associated with aging in the blood of women and tissues of old mice. Zoledronate has been used for decades to counteract bone mass loss. The authors of a new study measured changes in the blood of women, as well as in the hearts, livers, and intestines of old mice, and in human cells. They investigated how the drug may affect cells outside the skeleton. Bisphosphonates suppress the activity of osteoclasts, cells that break down bone tissue. Zoledronate was long considered a drug that works almost entirely within the skeleton. However, trials and observations of patients have raised another question: does it penetrate other tissues and change processes associated with aging? On July 15, a study by a team from Oxford University presented data from three levels. The authors examined the plasma - the liquid part of the blood - of 36 women over 65 years old with osteopenia, reduced bone density. After 18 and 36 months of infusion of 5 mg of zoledronate, about 400 out of five thousand measured proteins changed in it. Part of the changes affected proteins associated with DNA damage, mitochondrial dysfunction, and inflammatory substances that are released by aging cells. Plasma shows the trail of the drug's action, not the number of aging cells. A recent review of human trials came to a similar distinction: inflammatory proteins in the blood usually change more noticeably than direct signs of accumulation of old cells in tissues. Therefore, this human part of the study reveals a measurable signal, but does not answer whether the organism has become younger. The authors gave zoledronate to six old mice for two months and compared their organs with those of peers without the drug and young animals. In the heart, liver, and intestine, gene expression changed, and the calculation of cellular composition approximated the profile of young mice. The study links the signal from human blood to specific tissues where it can be further tested. The search for a mechanism led to heart cells. Labeled drug penetrated cardiac, hepatic, and renal cells. Low concentrations of zoledronate weakened cellular aging after DNA damage. The authors found a chain involving PHB2 - a protein that supports mitochondrial stability - and MEF2A, a regulator of heart cell function. When researchers turned off MEF2A, the protective effect of zoledronate almost disappeared. A common infusion quickly binds to bone, and then the drug is excreted by the kidneys. In cellular experiments, the effect appeared at low constant concentrations, which such a regimen does not predictably create outside the skeleton. The next test should check the delivery of zoledronate to tissues, its safety, and its impact on organ functions in humans. The current work provides specific cells, proteins, and measurement methods for this.

🔗 Read original →

Aran Nayebi and Daniel Yamins have derived a theorem about when two neural networks, solving a complex task, match at the level of individual computations. In the preprint, the authors set conditions for networks with ReLU and softplus activation functions. If two networks solve a sufficiently difficult common task and their representations can be linked by a linear transformation, individual computational directions may also obtain correspondences. Another theorem describes how such a correspondence can spread from the last layer to the early ones. In the preprint, published on July 9, Nayebi and Yamins dissect a long-standing observation from NeuroAI - an area where artificial neural networks are compared to brain function. Researchers show the same images to an animal and a model, and then check if the model's internal signals predict the responses of neurons. In a 2014 study, models were trained to recognize objects under changes in pose, size, and background. The more accurately they solved this task, the more accurately they predicted the responses of two areas of the macaque's visual cortex - V4 and IT. But a linear map can link large sets of signals, mixing the contribution of individual units. Therefore, it does not show by itself whether the model and the brain perform the same individual computations. Weak matching means that the activity of one layer can be translated into the activity of another by a linear rule. Strong matching means the correspondence of individual directions within a layer: for example, a filter that responds to an image edge at a certain angle. Nayebi and Yamins' theorem applies to networks with ReLU and softplus. ReLU converts a negative input to zero, so when crossing the threshold, the response gets a kink. Softplus has a smooth transition, but leaves curvature. If representations remain linearly comparable before and after such a nonlinear transition, the map between them must preserve the traces of individual used axes. Arbitrary mixing of axes will not do this. Therefore, provided that the task and the next layer actually use these directions, they can be matched with precision up to permutation and scale. "The harder the task, the fewer its solutions and the more likely their similarity," Daniel Yamins writes in an explanation of the theory. The authors call a hard task one that cannot be solved with a given accuracy, engaging only a few nonlinear axes in a given layer. The minimum number of axes needed, they call the budget of used axes. The more of the layer the task requires, the more of the axes the theorem guarantees correspondence between networks. Another theorem describes the "zipping" of hierarchies. It requires minimality: hidden functions at each step must make distinguishable contributions to the next layer. Then weak matching on the last comparable layer allows recovering correspondences in early layers for almost all weight settings; special exceptions the authors leave outside the result. In an approximate version, transitions between layers must be regular, i.e., not collapse different signal changes into one. Then a small error on the last comparable layer limits the fraction of axes that diverge earlier. The article suggests checking on brain data how much natural tasks engage many axes, whether minimality is satisfied, and whether training leads to exceptional weight settings. A simple task can be solved in many different ways. The authors suggest that tasks with natural images and situations for an animal may more strongly narrow down the set of solutions and thus increase the chance of matching the model with the brain at the level of individual computations.

🔗 Read original →

Kalshi opened pilot prediction markets for clinical trial outcomes and FDA decisions on July 16. Kalshi and AppliedXL launched pilot contracts for individual late-stage clinical trials and FDA decisions - those of the American drug regulator. The contract price shows the probability of the outcome that market participants are currently assuming. The stock price of a biotech company depends on many factors: the data of one trial, the amount of money, management decisions, and other drugs in development. Kalshi's contract puts one question into a separate market. Among the first questions are: will the POLARIS-AD study of the AR1001 drug for early Alzheimer's disease reach its primary endpoint, i.e., a pre-designated main result, and will the FDA approve the anito-cel cell therapy for multiple myeloma. If the contract costs 72 cents, market participants at that moment estimate the chance of a "yes" outcome at approximately 72%. Buyers and sellers bet differently, and the price collects their deals into one estimate. The effectiveness of the drug is evaluated based on trial data, the decision to approve is made by the FDA, and the market price reflects current deals. It is also influenced by liquidity, the composition of participants, the moment of trading, and market sentiment. The rules for determining the outcome of the contract are established in advance. Kalshi specifies the question, term, criteria, and public source or order of sources. AppliedXL, a company that analyzes public data on drug development, monitors the named registers and documents, conducts a check with human participation, and prepares an analysis, while Kalshi makes the final decision. "Clinical trial results and regulatory decisions are rarely collected in one final document. They need to be matched with the primary source and criteria set before trading begins," said Francesco Marcon, CEO of AppliedXL. Public quotation can change a patient's or doctor's attitude towards a study, so the pilot covers late-stage trials after patient enrollment is completed. Market participants confirm their place of work. Kalshi's rules prohibit trades by people with substantial non-public information and those who may influence the outcome. Such information can be obtained through a consultant, contractor, professional or personal connections. Kalshi checks information about employers and monitors suspicious trades. In June, Robin Hanson proposed a closed market where experts bet on scientific articles that the company would later base a biotech project on. Kalshi applies the prediction market to the next stage: after selecting a candidate, participants trade the probability of a pre-designated clinical or regulatory outcome. Before the trial results or FDA decision appear, the debate about the chances gets a public price.

🔗 Read original →

On July 16, in Science, a Stanford team's study found that in older mice, the signal through EP2 weakened the work of tissue macrophages. When the authors disabled this receptor only in macrophages, they again cleared aging neutrophils, and the animals' heart, muscle, memory, and other organ functions were preserved. Neutrophils are the most numerous and shortest-lived white blood cells. They are the first to attack an infection and then must quickly disappear: tissue macrophages, the permanent immune cells of organs, engulf and break them down inside themselves. In one day, the human body produces more than 100 billion neutrophils. Macrophages must continuously free organs from this mass of cells. With age, this process failed in mice. In the liver, spleen, bone marrow, and other organs, neutrophils with signs of cellular aging accumulated. They released damaging enzymes and triggered NETosis - the release of networks of DNA and proteins that neutrophils use against microbes. In tissues, these networks and released substances gave inflammatory stress to neighboring cells. The authors found a brake in the macrophages themselves. Prostaglandin E2 - a signaling fatty molecule, the amount of which grows during inflammation - turns on the EP2 receptor on their surface. EP2 disables the first step of cleanup: weakens the work of integrins, proteins that grab. The macrophage worse holds the neutrophil and does not engulf it in a phagolysosome, an internal bubble for breaking down prey. A review of aging macrophages in vascular plaque had already described the loss of cleaning function in one organ; the Tan team named the molecular brake of such a failure in several tissues at once. The team genetically disabled EP2 only in tissue macrophages. In old mice, the clearance of neutrophils returned, and the indicators of fragility, loss of muscle mass, obesity, heart function, memory, and inflammation approached those of young animals. An experimental EP2 inhibitor in 22-month-old mice also reduced the number of aging neutrophils and restored their absorption by macrophages over two months. One path to therapy for aging is to directly remove aging cells. This work suggests restoring the immune system's cleanup of one particularly massive class of cells. In human liver and heart tissues, the authors saw the same age-related pattern: more EP2 in macrophages, more aging neutrophils, fewer contacts between them. The transition to humans will require a selective and safe EP2 inhibitor: the current data show a target and mechanism, but not a ready-made drug.

🔗 Read original →

On July 17 in Nature Aging, a study by Marco Demaria's group from Groningen was published. The authors linked the work of CDK4/6, retinoic acid receptor RARα, and the inflammatory secretions of senescent cells; two interventions in this chain improved physical tests in old mice. A senescent cell stops dividing after damage, but remains in the tissue. Many such cells release signaling substances that support inflammation around them. This set is called SASP, and its NF-κB-controlled part is often associated with age-related inflammation: NF-κB is a protein switch that turns on immune response genes. In June, another Nature Aging study linked SASP to the release of nuclear RNA-DNA hybrids into the cytoplasm and the activation of cGAS-STING. Demaria's group approached the same inflammatory secretions from a different side: through CDK4 and CDK6 - enzymes that normally help the cell prepare for division. The authors took already senescent cells and gave them a short course of abemaciclib. The inflammatory genes of SASP began to work weaker; genetic knockout of CDK4 and CDK6 gave a similar result. Abemaciclib changed the secretions of already aging cells, rather than removing them from the tissue. Such agents are called senomorphics: they try to suppress the harmful behavior of the cell, while keeping it in place. Further, the team traced the chain: CDK4 and CDK6 interacted with NF-κB, and CDK4 also interacted with RARα, a retinoic acid receptor, a derivative of vitamin A. Abemaciclib disrupted these interactions. A separate RARα antagonist, substance agn194310, also weakened the inflammatory secretions. The study suggests the CDK4/6-RARα-NF-κB axis as a new target for the search for senomorphics. In 22-month-old mice, both substances reduced systemic signs of this inflammatory secretions and improved physical performance. The authors administered the drugs for two months; each of the four groups had four animals. The small experience requires independent repetition, especially since abemaciclib is used against some types of cancer and has toxicity. The boundary of the result is visible in another task. In a 2022 study by the same laboratory, CDK4/6 inhibitors introduced previously dividing normal cells into a special senescent state. A fresh preprint by another team saw the later inclusion of part of the NF-κB-dependent SASP in such cells. The current article examines already existing inflammatory senescent cells. These two states require different safety checks.

🔗 Read original →

Microgravity weakens cell contact with tissue and slows down protein assembly in mitochondria. On June 30, a study of cells grown on the ISS was published in Nature Communications: under microgravity, mitochondrial ribosomes assembled proteins more slowly. The authors traced the path from cell attachment to the surrounding tissue to the chemical tuning of this protein factory. Unloading and fixation of the hind limbs of mice gave the same signature in the soleus muscle. Mitochondria make some proteins themselves, with their own genome coding 13 components of the respiratory chain - a machine that converts food energy into ATP. Therefore, mitochondrial translation is important for muscle cells: the speed at which their internal ribosomes read RNA and assemble these proteins. The team of Taishi Wakigawa and Yusuke Kimura grew human cells on the ISS for 24 and 48 hours. A centrifuge on the station, which created normal Earth gravity (1g), served as a control. After 24 hours in microgravity, fewer ribosomes worked on mitochondrial RNA, while the amount of RNA itself changed little: protein assembly slowed down. In worms that lived on the station for four days, the same group measure of translation efficiency decreased. The authors reproduced the effect on Earth in a three-dimensional clinostat - a device that constantly changes the position of cells and mimics the absence of a constant gravity vector. The signal decreased within an hour, returned to its initial level under normal gravity, and increased under tenfold overload. The solution was found outside the cell. Laminin is a protein of the supporting tissue; integrins serve as molecular anchors for it. The better the cell attached to laminin, the faster the mitochondria assembled proteins. An integrin blocker gave the opposite effect and reduced oxygen consumption by mitochondria. Contact with laminin involves a chain of proteins: FAK - an enzyme at the cell attachment site, then RAC1 and PAK1. It changes the work of the BAD protein at the outer mitochondrial membrane and triggers fatty acid synthesis inside it. This process consumes malonyl-CoA, leaving fewer malonyl marks on the translation apparatus, which allows ribosomes to start working faster and elongate the protein chain. In eight-week-old mice, the authors unloaded and fixed the hind limbs for 14 days. In the soleus muscle, both mass and mitochondrial translation decreased simultaneously. The authors checked the chain in cells, worms, and young mice, but have not yet studied old muscle and strength recovery.

🔗 Read original →

Scientists appear to have found evidence that aging is a loss of cellular information, not simply the accumulation of damage.

A new preprint from the New York Genome Center has not yet been peer-reviewed. The work was performed on mouse models. Its translation to humans remains to be verified.

The researchers developed SeqTag technology and measured gene expression, chromatin accessibility, and histone marks in the same cells.

The authors found that in young cells, the three regulatory layers operate asynchronously but synchronize quickly. With age, this coordination breaks down. This is called molecular asynchrony.

This provides direct quantitative confirmation of the Information Theory of Aging (ITOA), which is being developed by David Sinclair, whose startup recently received FDA approval. His theory states that DNA barely changes during aging; the system that reads it changes.

Sinclair has long suspected that this process is reversible; experiments with partial reprogramming demonstrate tissue rejuvenation through the restoration of epigenetic patterns.

What practical changes does this make?

The damage accumulation model sets a therapeutic goal: slowing or repairing damage.

ITOA, however, has a different goal: restoring regulatory synchronization. These are different targets and different pharmacological strategies.

Altos Labs, Rejuvenate Bio, and several other companies are currently working on the latter.


https://www.biorxiv.org/content/10.64898/2026.06.02.729594v1

A review offers an explanation for why one aging target is more effective in worms than in mice. On July 12, in Mechanisms of Ageing and Development, a review was published on why anti-aging interventions often have a significant effect on simple animals and a much smaller effect on mammals. The authors collected data on worms, flies, and rodents. They suggest looking for the reason in the connections between tissues, hormones, and feedback that change the response of the entire organism. Gerontology has long seen this difference. A mutation in the signaling pathway through which insulin and IGF-1 regulate growth and metabolism can double the life of the worm C. elegans. In mice, rapamycin - one of the most studied anti-aging drugs - gave a much smaller result: when it was started at 600 days of life, the age at 90% mortality increased by 14% in females and by 9% in males. In worms, a small set of pathways simultaneously regulates nutrition, stress response, reproduction, and cell repair. The body of mammals distributes these tasks among many tissues. The liver, immune system, fat tissue, muscles, gut bacteria, and hormonal signals constantly change each other's state. The authors call the complexity of the organism the number of such connections and reserves, rather than the size of the body or the length of the genome. The authors call the strength of a single target the leverage of the pathway. The more an organism can change its life by affecting one pathway, the longer this lever. Against it works systemic buffering: backup genes, parallel signaling chains, and feedback between organs return the organism to a working state after intervention. According to this scheme, a drug can precisely alter mTOR - a cellular regulator of growth and resource expenditure - or another known pathway, but its effect will encounter several responses at once. Another tissue compensates for the shift; a hormone changes metabolism; gut bacteria change the availability of a molecule; the organism delivers and processes the drug in its own way. The more such connections, the harder it is for one target to shift the lifespan of the entire body. In mice, there is already an example of such a search: a combination of rapamycin and trametinib increased median life by approximately 30%, stronger than each drug separately. The new review raises an additional question: what combinations need to be selected, taking into account the responses of different tissues to each target. The article does not measure "buffering" with one device and does not establish a limit to human life. This is a qualitative review, not an experiment with a new therapy. It can be tested: comparing which compensatory responses are included after intervention in different tissues, and determining whether combinations of interventions enhance each other. The next generation of research should map: which tissue cancels the beneficial effect, which signal it does this with, and in what sequence to intervene, so that compensation from other organs does not cancel the result.

🔗 Read original →

AI can predict proteins, but therapy remains in the lab, factory, and long money - Dorothy Chow's argument. On July 16, former head of Google DeepMind's public engagement lab, Dorothy Chow, explained why computational breakthroughs alone do not accelerate biology. She suggests funding the entire path from prediction to testing and production. In a conversation with the Foresight Institute, Chow begins with AlphaFold. This system predicts a protein's three-dimensional shape from its sequence; knowing the shape helps understand where a drug molecule or antibody can bind to it. The model has made available the structures of over 200 million proteins. However, a long chain of work remains between the protein shape on the screen and a drug for humans. The success of AlphaFold relied on open data and a common way to verify results. The Protein Data Bank is a global archive of verified protein structures; CASP is a blind test where teams predict forms that have been found experimentally but not yet published. In the AlphaFold2 paper, researchers showed near-experimental accuracy for most proteins in CASP14. Such verification allowed comparing models by accuracy, not by the persuasiveness of presentations. After such a prediction, the expensive part begins: testing the candidate in a wet lab, where cells and tissues are physically worked with, and setting up production. Physical verification and the factory require time, infrastructure, and capital; Chow calls this gap the main obstacle after computation. According to Chow, a venture fund usually waits for an exit from investment within a 5-10 year horizon, and government funding often divides biology into narrow disciplines and annual budgets. She proposes mixed funding: grants and philanthropy pay for the long, risky part, and private capital scales up what has passed verification. An example is the pre-ordered vaccine purchases during COVID-19: the state reduced the risk of production, and companies could act faster. Chow suggests gathering data, independent verification, labs, production, and suitable money in advance for the next big idea. Then, AI can take successful predictions to testing and application, rather than stopping at the screen.

🔗 Read original →

PeptAI stated that its agent, after laboratory testing, independently modified the search for a peptide against VEGFR2 - a target associated with tumor vascular growth. According to the company, the program generated thousands of variants, selected several, paid for binding measurement, and received the results back. PeptAI wrote that these data forced the system to change its peptide generation approach and exclude problematic target areas in the new round. In April, PeptAI showed nine computational checks that the program runs peptides through before transferring them to an external laboratory. In May, its agent proposed 306 peptide variants of MOTS-C and an experimental plan; the candidate synthesis had not been performed yet. On July 17, PeptAI wrote in a new report: "The agent designs a candidate, pays the laboratory for verification, and receives the binding result back, and then starts the next round itself." The company claims that the agent generated thousands of peptides for VEGFR2, selected several, and paid for laboratory verification. VEGFR2 is a receptor on vascular cells: it sends a signal that helps grow new vessels, including those that feed tumors. PeptAI wrote that the positive control and a specially modified variant bound to the target, while the negative control signal did not. The agent took this result as feedback: the next round will use BindCraft - a program for designing proteins capable of binding to a given target - and will avoid known problematic areas on the VEGFR2 surface. The company remains the sole source of these data: the post lacks sequences, protocols, numerical measurements, or independent confirmation. Binding verification answers a narrow question: does the peptide bind to the target in a specific analysis? A therapeutic program then needs data on action in cells and organisms, selectivity, safety, and reproducibility. The model can rank thousands of sequences, but a physical experiment shows where its prediction met the molecule. For the agent, pairs of "sequence - result" become memories of which ideas withstood the test. If the result really changes the next search, each success and each failure narrow the space of the next experiment.

🔗 Read original →

Carl Pfleger has urged Brian Johnson to invest in companies and research on aging. Investor and founder of the AgingBiotech.info catalog, Carl Pfleger, has called on Brian Johnson to direct a significant portion of his money and public influence towards aging research. His thesis is as follows: personal measures help one survive until future therapies, and capital for laboratories, biotech, and testing regulations can bring those therapies closer. On July 17, Carl Pfleger wrote that Johnson is misallocating his priorities. Pfleger assumes that a 49-year-old person has decades of life ahead, and therefore, interventions that gerontology will create during this time will have a greater impact on his fate. "What the field of aging will be able to create in the next three to four decades will be more important for his life than everything available today," Pfleger writes. A personal protocol answers the question of how to reduce the risk of death now. Sleep, nutrition, training, disease treatment, and available medicine give a person time. Johnson has already turned this approach into a service: in June, he launched Immortals Medicine, where doctors remotely prescribe prescription medications from his protocol. Pfleger asks a different question: what does a wealthy supporter do after they have already received this time reserve? He suggests financing non-profit research, investing in companies that translate biological ideas into medicines, and advocating for regulations that allow for faster testing of therapies against age-related diseases. Gerontology studies the mechanisms of aging; without money for experiments, testing, and production, its discoveries will remain as articles and mouse models. This position has a mechanism. Personal expenses change one person's health through already available measures. Donating to a laboratory, investing in a biotech company, or a political campaign can pay for experiments, teams, and clinical trials. A successful therapy can then help many people, including the one who helped it appear. Pfleger believes that it is here that a wealthy immortalist has the greatest return on the next dollar: supporting future ways to repair the causes of aging. He also writes that he himself has invested in more than 30 rejuvenation companies; this is his own statement. Pfleger does not provide a public estimate of Johnson's expenses and does not calculate how much each of his options will accelerate the emergence of therapy. Therefore, the dispute remains a dispute over priorities. He suggests that a wealthy immortalist evaluate the next dollar based on how many research projects, companies, and trials that dollar can launch.

🔗 Read original →

A vaccine against six breaks in the KRAS gene was tested in people before pancreatic cancer appeared. On July 16, in an article in Cancer Discovery, a team from Johns Hopkins University described the first small clinical trial, phase I, with 20 people who have a hereditary risk of pancreatic cancer and suspicious changes on scans, often a small cyst. In 18 participants, T-cells - cells of the immune system that recognize the altered KRAS - appeared; such cells were found in the blood for up to two years. Over a median observation period of 16.5 months, cancer did not develop in any of the participants. In people with a hereditary risk of pancreatic cancer, doctors usually try to catch it with regular scans. If a cyst or another lesion starts to look dangerous, doctors may remove part of the pancreas. Early pre-cancerous cells can be too small to see on a scan. The Johns Hopkins University team chose KRAS - a gene whose breaks trigger the growth of more than 90% of such tumors - as a target. The same breaks often appear in pre-tumor cells as well. The mKRAS-VAX vaccine contains fragments of the six most common KRAS variants. After vaccination, the immune system learns to recognize these fragments and seek out cells that display them on their surface. People have already been given a vaccine against a common tumor mutation after diagnosis: in the IDH1-vac trial, 33 patients with brain tumors received it along with surgery, radiation, and chemotherapy. The participants in the new study had not yet developed cancer. All had a hereditary predisposition and a change in the pancreas that doctors usually monitor. Participants received three initial doses under the skin and one booster. In 18 out of 20, two types of T-cells appeared: some ready to immediately attack the target, others storing immune memory. Part of the cells induced by the vaccine persisted in the blood for up to two years. Undesirable phenomena did not exceed the first or second degree. Researchers also looked at cysts. In the vaccination group, they decreased or disappeared in 37.5% of participants; in a comparable unvaccinated group - in 6.8%. People were not randomly assigned to groups, so this number does not separate the action of the vaccine from differences between groups. The first phase tested safety and the ability to induce an immune response. The authors reported on a recruiting study where they will check if T-cells from the blood reach pre-tumor lesions in the pancreas itself. A larger comparison should measure whether the number of cancer cases decreases.

🔗 Read original →

Exosomes delivered RNA through the brain's defense and turned off inflammatory neuronal death in mice. On July 11, a study on siRNA - a short RNA that makes a cell stop producing a selected protein - was published in Advanced Science. The authors packaged siRNA against RIPK3 into exosomes, administered them to mice intravenously, and obtained a signal in the brain, suppression of the target in neurons, and better results in memory tests in a mouse model of Alzheimer's disease. It can be easier to come up with a molecule against a brain disease than to deliver it to a neuron. The blood-brain barrier consists of tightly connected vascular cells and barely allows large RNAs from the blood to pass through. Free siRNA is quickly destroyed. Without delivery, even precise RNA remains outside the target cell. A team from Harbin Medical University took exosomes, natural bubbles that cells use to exchange substances. They placed the RVG peptide on their surface: it binds to receptors on the wall of brain vessels and neurons. They loaded siRNA against RIPK3 - a protein involved in triggering necroptosis, an inflammatory form of cell death - inside. During necroptosis, a neuron bursts and releases alarm signals; they raise inflammation around it. The authors checked the entire chain. In a barrier model, a fluorescent label passed into the "brain" chamber. After injection into mice, the exosome signal reached the brain in about six hours. In neurons, siRNA exited from lysosomes - intracellular bubbles where foreign cargo is usually digested - into the cytoplasm and reduced the activity of RIPK3 and its partner MLKL. Further, they checked the disease. Triple APP/PS1/TAU mice carry mutations that cause them to accumulate amyloid and pathological tau protein early, lose synapses, and lose memory. After intravenous administration of siRNA-exosomes, the animals better recognized a new object and found the previous platform location in a water labyrinth. In the brain, the proportion of cells with active RIPK3 decreased from 28.48% to 12.19%, and with active MLKL - from 24.42% to 12.45%. In human cortical organoids, the system also reduced the necroptosis signal and restored the synaptic protein GRIA1. The study addresses two separate challenges: blocking the death pathway and delivering a gene switch to a neuron. Necroptosis has long been suspected in neuronal loss in Alzheimer's disease: in a 2023 experiment, human neurons in a mouse brain were protected by suppressing RIPK1, RIPK3, or MLKL. The new study checks transport: can a gene switch be brought from a vein directly to a vulnerable neuron. Organoids do not have vessels and a full-fledged immune system, and exosomes for experiments were obtained from mouse cell lines. The fluorescent signal in the brain does not yet measure the exact proportion of the administered dose in human tissues. For human trials, data from primates are needed: long-term safety, organ distribution, and production of identical batches of exosomes.

🔗 Read original →

On July 16, Science journal editor-in-chief Holden Thorp described a bottleneck in scientific AI. The generation of hypotheses, analyses, and manuscripts is accelerating, while the verification of their origin and validity remains the work of humans. In a July 16 editorial in Science, Thorp suggests measuring scientific AI by two speeds. The first shows how many hypotheses, calculations, and articles a machine produces per day. The second shows how many of them researchers can verify to rely on the conclusions. AI agents are accelerating the first speed; the second is limited by the number of checks that people can perform. The reason is simple. A finished article hides a long chain of decisions: which data the system chose, which it excluded, which metric it assigned as primary, how many options it tried before achieving a successful result. If this chain was assembled by an agent, the editor needs more than just to read the smooth text. They need the original data, code, and action log to reproduce the work process. In December 2025, the authors of a study on two open autonomous scientific systems found four classes of hidden errors: inappropriate testing, data leakage, incorrect success metrics, and result selection after the experiment. The final manuscript may hide such decisions. A complete action log and code allow them to be seen. In May, the authors of a preprint on fictional bibliographic references, i.e., works before peer review, checked 111 million references in 2.5 million works. They estimated the number of non-existent references in 2025 to be at least 146,932. Each such reference forces the editor, reviewer, or reader to manually search for the real basis of the statement. A scientific agent must transmit a verifiable trail along with the result: the original question, data, intermediate decisions, and final conclusion. Such a trail turns verification into part of the research, not just a review of beautiful text after its appearance. Dorothy Chow described the path from protein prediction to a drug: after calculation, laboratory testing, production, and long funding remain. Thorp adds editorial verification to this chain. In biology, an error in target, model, or biomarker selection leads to months of laboratory work and money needed for the next intervention. The speed of scientific AI is measured by the speed of verification of its conclusions. Journals, laboratories, and foundations need a reproducible chain that leads to each conclusion.

🔗 Read original →

Nerve endings in the skin send a signal to collagen-producing cells that helps to restrain their aging. On July 17, a study on the connection between nerve endings and skin condition was published in Cell. The study, which involved 148 people, found an age-related decline in Nefh and collagen; the authors then tested the causal chain in skin models. It involves glutamate, a chemical signal that nerve cells use to transmit messages to neighboring cells. Fibroblasts produce collagen, which keeps tissue elastic. As people age, they enter senescence - they stop dividing normally and change their environment. The new work checks how the nerve fiber signal affects fibroblasts in a skin model. The authors add a nerve ending to this picture. Fibroblasts often came into contact with nerve fibers carrying Nefh. This protein was predominantly found in neurons that release glutamate. Nefh is a neurofilament heavy chain protein that supports the neuron's framework. The loss of Nefh changed the state of fibroblasts through a neuronal signal. When researchers removed Nefh from neurons that release glutamate in skin models, fibroblasts more often entered a senescent state, and the skin lost collagen. Denervation of the skin had a similar effect: signs of aging intensified along with the loss of collagen. Further, the authors dissected the pathway. Cdk5 interacts with both Nefh and Vglut2 - a transporter that loads glutamate into vesicles for release from the neuron. In fibroblasts, the action of glutamate depended on Slc1a3, a carrier protein. In models, the addition of glutamate weakened signs of senescence and maintained collagen production. In skin models, disruption of the signal from a neighboring nerve changed the state of fibroblasts and collagen content. Studies of skin aging can now test how to preserve the connection between the nerve ending and the tissue it serves. In human samples, the work shows an age-related correlation, and the removal of Nefh and addition of glutamate were investigated in skin models. Separate data on signal delivery, safety, and duration of effect are needed for therapy. In models, the loss of Nefh in neurons that release glutamate reduced this signal, enhanced fibroblast senescence, and decreased collagen content.

🔗 Read original →

SonoThera claims to have delivered a full-size dystrophin gene to monkeys' muscles without a virus. Gene therapy is hindered by delivery: a large gene needs to be introduced into the necessary cells, and a common viral vector often cannot be administered repeatedly. SonoThera demonstrates an alternative approach in animals: DNA is introduced with microbubbles, and then focused ultrasound temporarily opens a pathway into cells. The company has no clinical data or peer-reviewed article. Duchenne muscular dystrophy occurs due to defects in the dystrophin gene. Without this protein, muscle fibers gradually deteriorate. The full version of the gene is too large for a conventional viral vector, so viral therapies usually carry a shortened micro-dystrophin. On July 2, Elixirgen described a different approach to the same goal: localized mRNA with full-size dystrophin should remain at the injection site. SonoThera is attempting to deliver DNA with ultrasound directly into multiple muscle tissues. According to biologist Avi Ro, the company introduces DNA with microscopic gas bubbles and directs ultrasound to the target tissue. The bubbles help make the cell membrane permeable for a short time, after which the DNA enters. No virus is needed; theoretically, such a procedure can be repeated. On a poster, the company showed expression of full-size human dystrophin in the muscles, heart, and diaphragm of mice with a Duchenne model. In the skeletal muscle of monkeys, SonoThera claims up to 50% of the normal protein level. This figure has a specific limitation: the used antibody detects both the monkey's natural protein and the delivered human protein. Therefore, the authors separately searched for human RNA and a specific label on the delivered protein in the treated muscle fibers. On July 17, STAT quoted two Duchenne researchers who found the results in animals too unusual to accept without further verification. SonoThera has no human trials yet; the company plans its first trial for 2027, and the disclosed data exists in the form of a conference poster. Ultrasound needs to prove two properties in human muscles: to transport large DNA into a sufficient number of cells and to withstand repeated dosing without hazardous consequences. Then, part of gene therapy may be able to move beyond the size of a viral shell and transport more complete repair programs into tissues.

🔗 Read original →

According to mathematician Kerger, GPT-5.6 Sol proposed a proof of the limits of optimization; Lean checked a new lower bound. On July 14, Berkeley instructor Philip Kerger posted a preprint on the problem of convex optimization, where the algorithm receives only numerical answers to a function. According to Kerger, GPT-5.6 Sol found a proof construction in a session lasting around 2.5 hours; the open Lean project gathers a new lower bound with precisely specified accuracy. Let's present the problem: one needs to find the lowest point of an unknown "bowl" in a space with d parameters. The algorithm chooses a point and receives one number - the height of the bowl at that point. The next move must be chosen based on the history of such numbers. How many measurements are inevitably required before one can guarantee approaching the minimum? At an accuracy of the order of 1/√d, Protasov's 1996 method gave an algorithm with approximately d² log²d measurements. The strictly proven ban was much weaker: around d measurements. Between these estimates, there remained the possibility of an algorithm that would be radically more economical. In Kerger's preprint, a new lower bound is stated: any deterministic algorithm will require approximately d²/log(d+1) queries in the worst case. It almost closes the previous gap to within logarithms. Here, Lean appears - a language and program for formal proof verification. Each line of the proof receives an exact logical type, and the program's core re-checks whether the conclusion follows from the previous steps. The open code conducts this procedure for precisely the new lower bound: for each algorithm with a limited number of queries, an admissible convex function is constructed on which that algorithm misses the specified accuracy. The Lean project checks the lower bound. The upper estimate from Protasov's work, the two-sided formula for complexity, and the transfer to mixed-integer problems remain in the manuscript; they will be evaluated by mathematical reviewers. On July 16, the chief editor of the Science journals, Holden Thorp, wrote that AI can write more science than people can check. For arguments that can be recorded in strict logic, Lean sets a sequence: the model proposes a proof construction, the core checks a specific statement, and mathematicians evaluate the setup and conclusions.

🔗 Read original →

When scientists turned off nine old genes, dietary restriction extended the life of flies more strongly. On July 16, a study of eight species of Drosophila was published in EMBO Reports. The authors found a common response to dietary restriction, selected 15 evolutionarily old genes, and temporarily turned them off in adult flies. In nine interventions, lifespan on a restricted diet increased. In fly experiments, dietary restriction looks like a series of diets with different proportions of yeast - the main source of protein. A team from the University of Sheffield gave eight species of Drosophila five such diets. In five species, life was longer on less rich food, with each species having its own optimal proportion of yeast. In flies with a diet for maximum lifespan, egg laying also decreased. Then the researchers looked at which genes changed activity under such nutrition. In six species, they compared 6,926 common genes. The response turned out to be similar in direction: the same groups of genes in different flies more often turned on or off together. Most of the most responsive genes, however, arose relatively recently in evolution and are found mainly in arthropods. The common RNA signature does not yet indicate a common mechanism of longevity. This signature mixes ancient processes and local adaptations of each species to food deficiency. The authors identified 15 genes that changed activity consistently and existed even in distant animal ancestors. Each of them was temporarily turned off by RNA interference: this method forces the cell to destroy the RNA of the chosen gene and reduces the production of the corresponding protein. In 12 interventions, lifespan changed. Nine enhanced the effect of dietary restriction. Five of these nine genes usually became more active under the most restrictive diet; their shutdown gave flies an even greater gain. The authors suggest that part of the response to food deficiency protects current physiology: the cell tries to conserve and redistribute rare substances, and this compensation partially offsets the life extension. Among the selected genes, sulfur-containing amino acid metabolism - cysteine, methionine, and serine - was particularly common. These molecules are involved in protein assembly, antioxidant protection, and one-carbon group metabolism. The authors received a direction for the next check: to determine which of such compensatory reactions limit the effect of diet and whether it is possible to influence them more precisely. A review of how tissues and feedbacks weaken single interventions against aging discussed this problem in complex organisms. The new work shows a possible special case even in flies: the organism itself includes responses to food deficiency, and some of them reduce the gain in longevity. The work covers adult female flies and diets with different proportions of yeast. The path to humans will require testing these targets in mammals and a separate assessment of safety. Currently, the most valuable result is the ability to search for a common mechanism among a huge list of changed genes: comparing species, selecting ancient candidates, and immediately testing whether they change the life of the animal.

🔗 Read original →